Market Pulse Archives

March 11, 2020, 8:10 a.m. EDT

UK biotech Tiziana Life Sciences says its TZLS-501 may be of use in treating coronavirus

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Tiziana Life Sciences Ltd. (TLSA)

or Cancel Already have a watchlist? Log In

By Ciara Linnane


UK biotech Tiziana Life Sciences Plc /zigman2/quotes/207307745/composite TLSA +0.36% said Wednesday its TZLS-501 treatment could be used for patients with the coronavirus that causes COVID-19 and are at risk of respiratory failure. The company is accelerating development of the treatment with Novimmune SA, a Swiss biotech company. "Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood," the company said in a statement. "An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness." Shares were up more than 300% premarket. The stocks of many small biotechs and medical device companies that have made announcements relating to the virus have rallied hard as the illness has spread around the world, even though experts caution it will take a long time to develop treatments.

US : U.S.: Nasdaq
$ 0.66
+0.0024 +0.36%
Volume: 71,244
Sept. 26, 2023 4:00p
P/E Ratio
Dividend Yield
Market Cap
$67.25 million
Rev. per Employee

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.